News
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
MIRA Pharmaceuticals announces preclinical data on SKNY-1, a next-gen oral drug targeting obesity and nicotine addiction. The acquisition of SKNY is pending regulatory and shareholder approval -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
MIRA Pharmaceuticals announces the acceptance of their lead drug candidate Ketamir-2 manuscript for publication in Frontiers in Pharmacology, showcasing its differentiated pharmacology and safety profile for CNS therapeutic use -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
MIRA Pharmaceuticals to engage in BIO One-on-One Partnering™ meetings at BIO International Convention 2025, advancing Ketamir-2 Phase 1, neuropathic pain study, and SKNY acquisition filings -
-
